RESUMO
BACKGROUND: There is increasing recognition of Crohn's disease (CD) in non-white populations. However, reports of racial disparities in the phenotype of CD are still inconsistent. AIM: : The aim of this study was to test the hypothesis that African American (AA) patients have higher incidence of severe fistulizing perianal Crohn's disease (FPD) compared with white patients. METHODS: Cross-sectional analysis of 333 adult CD patients treated at The Mount Sinai Hospital with infliximab between May 2011 and December 2011 was conducted. Self-reported race/ethnicity was recorded and proportions of each group with FPD were compared across the population. RESULTS: Among all 333 evaluable CD patients on infliximab, 73.6% were white, 11.4% AA, 13.2% Hispanic, and 1.8% Asian. Of these 333 patients, 88 had FPD: only 48 of these (54.5%) were white, whereas fully 18 (20.5%) were AA, 20 (22.7%) were Hispanic, and 2 (2.3%) were Asian. Thus, patients receiving infliximab for FPD were significantly more likely to be AA or Hispanic than white (AA vs. whites: risk ratio=2.63; 95% confidence interval, 1.74-3.96; P=<0.0001; Hispanics vs. whites: risk ratio=2.32; 95% confidence interval, 1.54-3.50; P=0.0001). There was no statistically significant difference between AA and Hispanics. CONCLUSION: CD patients at our medical center with FPD requiring infliximab therapy were significantly more likely to be AA or Hispanic.
Assuntos
Negro ou Afro-Americano , Doença de Crohn/etnologia , Fístula Retal/etnologia , Anti-Inflamatórios/uso terapêutico , Anticorpos Monoclonais/uso terapêutico , Asiático , Distribuição de Qui-Quadrado , Doença de Crohn/diagnóstico , Doença de Crohn/tratamento farmacológico , Estudos Transversais , Fármacos Gastrointestinais/uso terapêutico , Hispânico ou Latino , Humanos , Incidência , Infliximab , Cidade de Nova Iorque/epidemiologia , Razão de Chances , Fenótipo , Prevalência , Fístula Retal/diagnóstico , Fístula Retal/tratamento farmacológico , Fatores de Risco , Índice de Gravidade de Doença , Centros de Atenção Terciária , Saúde da População Urbana , População BrancaAssuntos
Doença de Crohn/diagnóstico por imagem , Endoscopia Gastrointestinal/métodos , Doenças do Esôfago/diagnóstico por imagem , Fístula Intestinal/diagnóstico por imagem , Adulto , Doença de Crohn/complicações , Doença de Crohn/terapia , Doenças do Esôfago/etiologia , Doenças do Esôfago/terapia , Feminino , Humanos , Fístula Intestinal/etiologia , Fístula Intestinal/terapiaRESUMO
Objectives and study aim Colonoscopy prevents colorectal cancer by removing adenomatous polyps, but missed adenomas lead to interval cancers. Different devices have been used to increase adenoma detection rates (ADR). Two such devices of interest are the transparent cap (Olympus) and Endocuff (ARC Medical). Our study aimed to compare differences in ADR between Endocuff-assisted colonoscopy (EAC), cap-assisted colonoscopy (CAC) and standard colonoscopy (SC). Patients and methods A sample size of 126 subjects was calculated to determine an effect size of 30â%. Patients undergoing screening or surveillance colonoscopy between March 2016 and January 2017 were randomized to SC, CAC or EAC groups. Three experienced endoscopists performed all colonoscopies. Patient demographics, procedure indication, Boston Bowel Prep Score (BBPS), withdrawal time, polyp size, location, histopathology, were analyzed. Results There was no difference in ADR (52â%, 40â% and 54â%) in the SC, CAC and EAC groups respectively ( P â=â0.4). Similar findings were also observed for proximal ADR (45â%, 35â%, and 50â%, P â=â0.4) and SSA detection rate (16â%, 14â%, and 23â%, P â=â0.5). EAC detected higher mean ADR per colonoscopy compared to CAC (1.70 vs 0.76, P â=â0.01). However, there was no significant difference in mean ADR per positive colonoscopy (2.08, 1.63, and 2.59, P â=â0.21). Conclusion In a randomized controlled trial comparing AC to CAC and SC, neither device conferred additional benefits in ADR among high detectors. When comparing each device, EAC may be better than CAC at detecting more total adenomas.
RESUMO
Autoimmune enteropathy (AIE) is rare but damaging. The lack of consistent objective findings makes diagnosis a challenge. A 45-year-old male developed noninfectious diarrhea with significant weight loss and electrolyte abnormalities. Computed tomography delineated enteritis. Colonoscopy and esophagogastroduodenoscopy showed villous atrophy, chronic inflammation, and ulceration of the terminal ileum and cecum. Pathology showed cryptitis with apoptosis and abscesses throughout the small and large bowel and absent goblet cells. Steroids rapidly improved symptoms. Anti-enterocyte antibody serologies were negative. Management can be challenging, and, in this case, the patient initially improved with budesonide and infliximab but required alternative anti-tumor necrosis factor therapy after relapsing. This is an unusual presentation of seronegative AIE, which should be considered in cases of persistent severe diarrhea.
RESUMO
This article contains a brief atlas for esophageal dysphagia, with an emphasis on endoscopic evaluation. Dysphagia refers to an abnormality with food propulsion, and it may be caused by oropharyngeal or esophageal disorders. Radiological modalities, endoscopy, and manometry play an important role in both the diagnosis and management of esophageal disorders.